YORVIPATH Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Yorvipath, and what generic alternatives are available?

Yorvipath is a drug marketed by Ascendis Pharma Bone and is included in one NDA. There are six patents protecting this drug.

This drug has ninety-eight patent family members in twenty-seven countries.

The generic ingredient in YORVIPATH is palopegteriparatide. One supplier is listed for this compound. Additional details are available on the palopegteriparatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Yorvipath

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 9, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for YORVIPATH?
What are the global sales for YORVIPATH?
What is Average Wholesale Price for YORVIPATH?

Summary for YORVIPATH

International Patents:	98
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	YORVIPATH at DailyMed

Drug patent expirations by year for YORVIPATH

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for YORVIPATH

Generic Entry Date for YORVIPATH^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS NDA: 216490 Dosage: SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for YORVIPATH

Drug Class	Parathyroid Hormone Analog

US Patents and Regulatory Information for YORVIPATH

YORVIPATH is protected by six US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of YORVIPATH is ⤷ Sign Up.

This potential generic entry date is based on TREATMENT OF HYPOPARATHYROIDISM IN ADULTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting YORVIPATH

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

FDA Regulatory Exclusivity protecting YORVIPATH

TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
Exclusivity Expiration: ⤷ Sign Up

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for YORVIPATH

See the table below for patents covering YORVIPATH around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Russian Federation	2014122036	ПРОЛЕКАРСТВО, СОДЕРЖАЩЕЕ САМОРАСЩЕПЛЯЕМЫЙ ЛИНКЕР	⤷ Sign Up
Australia	2009209565	Prodrug comprising a self-cleavable linker	⤷ Sign Up
Brazil	112019005793	compostos de pth com baixas proporções de pico-para-vale	⤷ Sign Up
European Patent Office	3981761	PRODUITS INTERMÉDIAIRES POUR PROMÉDICAMENTS (INTERMEDIATES FOR PRODRUGS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for YORVIPATH

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for YORVIPATH

Pharmacology for YORVIPATH

Patents protecting YORVIPATH

FDA Regulatory Exclusivity protecting YORVIPATH

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for YORVIPATH